Literature DB >> 12859274

Kaposi's sarcoma of the conjunctiva leads to a diagnosis of acquired immunodeficiency syndrome.

Katharina Schmid, Thomas Wild, Matthias Bolz, Reinhard Horvat, Wolfgang Jurecka, Martin Zehetmayer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12859274     DOI: 10.1034/j.1600-0420.2003.00105.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


× No keyword cloud information.
  6 in total

Review 1.  The role of infectious agents in the etiology of ocular adnexal neoplasia.

Authors:  Varun Verma; Defen Shen; Pamela C Sieving; Chi-Chao Chan
Journal:  Surv Ophthalmol       Date:  2008 Jul-Aug       Impact factor: 6.048

2.  Kaposi's Sarcoma of the Bulbar Conjunctiva in an Immunocompetent Patient.

Authors:  Dimitris Mikropoulos; Ioannis Mavrikakis; Nikolas G Ziakas; Anastasios G P Konstas; Kostas G Boboridis
Journal:  Case Rep Ophthalmol       Date:  2011-06-14

3.  Aggressive conjunctival Kaposi sarcoma as the initial manifestation of acquired immunodeficiency syndrome.

Authors:  Christopher Donovan; Hershel Patel; Sirikishan Shetty; Lauren Bierman; Jay M Lustbader; Aruoriwo M Oboh-Weilke
Journal:  Am J Ophthalmol Case Rep       Date:  2020-07-16

4.  A Case of Ocular Kaposi's Sarcoma Successfully Treated with Highly Active Antiretroviral Therapy (HAART) Combined with Docetaxel.

Authors:  Chongfei Jin; Hamza Minhas; Amandeep Kaur; Sreenath Kodali; Vladimir Gotlieb
Journal:  Am J Case Rep       Date:  2018-09-10

5.  Kaposi's sarcoma of the conjunctiva and the eyelid leads to the diagnosis of human immunodeficiency virus infection - a case report.

Authors:  Filipe Sousa Neves; Joana Braga; João Cardoso da Costa; Joaquim Sequeira; Sandra Prazeres
Journal:  BMC Cancer       Date:  2018-07-03       Impact factor: 4.430

Review 6.  Anterior segment manifestations of human immunodeficiency virus/acquired immune deficiency syndrome.

Authors:  Jyotirmay Biswas; S Sudharshan
Journal:  Indian J Ophthalmol       Date:  2008 Sep-Oct       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.